Annual CFF
-$10.71 M
+$2.85 M+21.03%
30 April 2024
Summary:
PharmaCyte Biotech annual cash flow from financing activities is currently -$10.71 million, with the most recent change of +$2.85 million (+21.03%) on 30 April 2024. During the last 3 years, it has fallen by -$15.34 million (-330.94%). PMCB annual CFF is now -112.26% below its all-time high of $87.31 million, reached on 30 April 2022.PMCB Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$10.17 M
+$525.20 K+4.91%
31 July 2024
Summary:
PharmaCyte Biotech quarterly cash flow from financing activities is currently -$10.17 million, with the most recent change of +$525.20 thousand (+4.91%) on 31 July 2024. Over the past year, it has dropped by -$10.92 million (-1458.59%). PMCB quarterly CFF is now -111.64% below its all-time high of $87.36 million, reached on 31 October 2021.PMCB Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$27.16 M
-$16.45 M-153.63%
31 July 2024
Summary:
PharmaCyte Biotech TTM cash flow from financing activities is currently -$27.16 million, with the most recent change of -$16.45 million (-153.63%) on 31 July 2024. Over the past year, it has dropped by -$26.10 million (-2469.93%). PMCB TTM CFF is now -131.07% below its all-time high of $87.41 million, reached on 31 January 2022.PMCB TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PMCB Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +21.0% | -1458.6% | -2469.9% |
| 3 y3 years | -330.9% | -111.6% | -131.1% |
| 5 y5 years | -557.1% | -3479.3% | -1583.3% |
PMCB Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -112.3% | +21.0% | -111.6% | +4.9% | -131.1% | at low |
| 5 y | 5 years | -112.3% | +21.0% | -111.6% | +4.9% | -131.1% | at low |
| alltime | all time | -112.3% | +21.0% | -111.6% | +4.9% | -131.1% | at low |
PharmaCyte Biotech Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| July 2024 | - | -$10.17 M(-4.9%) | -$27.16 M(+153.6%) |
| Apr 2024 | -$10.71 M(-21.0%) | -$10.70 M(+52.0%) | -$10.71 M(+148.0%) |
| Jan 2024 | - | -$7.04 M(-1040.1%) | -$4.32 M(+308.6%) |
| Oct 2023 | - | $748.70 K(-88.1%) | -$1.06 M(-79.6%) |
| July 2023 | - | $6.28 M(-245.8%) | -$5.19 M(-61.7%) |
| Apr 2023 | -$13.56 M(-115.5%) | -$4.31 M(+14.0%) | -$13.56 M(+45.7%) |
| Jan 2023 | - | -$3.78 M(+11.6%) | -$9.30 M(+68.4%) |
| Oct 2022 | - | -$3.38 M(+62.0%) | -$5.53 M(-106.5%) |
| July 2022 | - | -$2.09 M(+4014.2%) | $85.22 M(-2.4%) |
| Apr 2022 | $87.31 M(+1783.0%) | -$50.80 K(<-9900.0%) | $87.31 M(-0.1%) |
| Jan 2022 | - | $0.00(-100.0%) | $87.41 M(+0.0%) |
| Oct 2021 | - | $87.36 M(>+9900.0%) | $87.37 M(+3002.0%) |
| July 2021 | - | $0.00(-100.0%) | $2.82 M(-39.3%) |
| Apr 2021 | $4.64 M(+70.1%) | $50.80 K(-233.0%) | $4.64 M(-22.4%) |
| Jan 2021 | - | -$38.20 K(-101.4%) | $5.98 M(-7.5%) |
| Oct 2020 | - | $2.80 M(+54.1%) | $6.47 M(+63.2%) |
| July 2020 | - | $1.82 M(+30.7%) | $3.96 M(+45.4%) |
| Apr 2020 | $2.73 M(+16.4%) | $1.39 M(+209.4%) | $2.73 M(+50.1%) |
| Jan 2020 | - | $450.00 K(+49.5%) | $1.82 M(-0.8%) |
| Oct 2019 | - | $301.00 K(-48.3%) | $1.83 M(+19.7%) |
| July 2019 | - | $582.50 K(+20.7%) | $1.53 M(-34.7%) |
| Apr 2019 | $2.34 M(-12.6%) | $482.50 K(+3.8%) | $2.34 M(-16.0%) |
| Jan 2019 | - | $465.00 K(>+9900.0%) | $2.79 M(+20.0%) |
| Oct 2018 | - | $0.00(-100.0%) | $2.33 M(0.0%) |
| July 2018 | - | $1.40 M(+50.0%) | $2.33 M(-13.3%) |
| Apr 2018 | $2.68 M(-45.1%) | $930.00 K(>+9900.0%) | $2.68 M(-24.5%) |
| Jan 2018 | - | $0.00(0.0%) | $3.55 M(-34.1%) |
| Oct 2017 | - | $0.00(-100.0%) | $5.39 M(+1.6%) |
| July 2017 | - | $1.75 M(-2.8%) | $5.31 M(+8.7%) |
| Apr 2017 | $4.88 M(+36.8%) | $1.80 M(-2.0%) | $4.88 M(+45.4%) |
| Jan 2017 | - | $1.84 M(-2332.9%) | $3.36 M(+8.9%) |
| Oct 2016 | - | -$82.30 K(-106.2%) | $3.08 M(-14.8%) |
| July 2016 | - | $1.33 M(+379.4%) | $3.62 M(+1.4%) |
| Apr 2016 | $3.57 M(-2.0%) | $276.50 K(-82.3%) | $3.57 M(-41.7%) |
| Jan 2016 | - | $1.56 M(+243.4%) | $6.12 M(+12.8%) |
| Oct 2015 | - | $455.10 K(-64.3%) | $5.43 M(+12.0%) |
| July 2015 | - | $1.27 M(-55.0%) | $4.85 M(+33.1%) |
| Apr 2015 | $3.64 M(-57.3%) | $2.83 M(+225.8%) | $3.64 M(-33.9%) |
| Jan 2015 | - | $868.90 K(-794.6%) | $5.51 M(+2.8%) |
| Oct 2014 | - | -$125.10 K(-285.9%) | $5.36 M(-21.9%) |
| July 2014 | - | $67.30 K(-98.6%) | $6.86 M(-19.6%) |
| Apr 2014 | $8.53 M | $4.70 M(+554.3%) | $8.53 M(+98.1%) |
| Jan 2014 | - | $718.00 K(-48.0%) | $4.31 M(+12.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Oct 2013 | - | $1.38 M(-20.5%) | $3.84 M(+43.9%) |
| July 2013 | - | $1.74 M(+266.2%) | $2.67 M(+118.4%) |
| Apr 2013 | $1.22 M(+12.1%) | $473.90 K(+90.9%) | $1.22 M(+26.2%) |
| Jan 2013 | - | $248.20 K(+18.9%) | $967.10 K(+7.5%) |
| Oct 2012 | - | $208.80 K(-28.0%) | $899.60 K(-1.6%) |
| July 2012 | - | $289.80 K(+31.5%) | $913.80 K(-16.1%) |
| Apr 2012 | $1.09 M(+286.8%) | $220.30 K(+21.9%) | $1.09 M(+2.3%) |
| Jan 2012 | - | $180.70 K(-19.0%) | $1.06 M(+11.3%) |
| Oct 2011 | - | $223.00 K(-52.1%) | $956.50 K(+30.3%) |
| July 2011 | - | $465.50 K(+138.1%) | $734.20 K(+160.6%) |
| Apr 2011 | $281.70 K(-4.9%) | $195.50 K(+169.7%) | $281.70 K(+203.2%) |
| Jan 2011 | - | $72.50 K(>+9900.0%) | $92.90 K(-14.3%) |
| Oct 2010 | - | $700.00(-94.6%) | $108.40 K(-67.9%) |
| July 2010 | - | $13.00 K(+94.0%) | $337.20 K(+13.8%) |
| Apr 2010 | $296.10 K(+2.4%) | $6700.00(-92.4%) | $296.20 K(-48.8%) |
| Jan 2010 | - | $88.00 K(-61.7%) | $578.70 K(+17.9%) |
| Oct 2009 | - | $229.50 K(-919.6%) | $490.70 K(+87.9%) |
| July 2009 | - | -$28.00 K(-109.7%) | $261.20 K(-9.7%) |
| Apr 2009 | $289.20 K(-82.0%) | $289.20 K(>+9900.0%) | $289.20 K(-38.5%) |
| Jan 2009 | - | $0.00(0.0%) | $470.60 K(-60.6%) |
| Oct 2008 | - | $0.00(0.0%) | $1.20 M(-3.2%) |
| July 2008 | - | $0.00(-100.0%) | $1.24 M(-23.0%) |
| Apr 2008 | $1.61 M(+47.8%) | $470.60 K(-35.1%) | $1.61 M(+1.2%) |
| Jan 2008 | - | $725.00 K(+1712.5%) | $1.59 M(+35.2%) |
| Oct 2007 | - | $40.00 K(-89.2%) | $1.17 M(-20.4%) |
| July 2007 | - | $369.50 K(-18.2%) | $1.47 M(+35.7%) |
| Apr 2007 | $1.09 M(-44.2%) | $451.50 K(+44.6%) | $1.09 M(-35.7%) |
| Jan 2007 | - | $312.20 K(-8.2%) | $1.69 M(-8.9%) |
| Oct 2006 | - | $340.00 K(-1999.4%) | $1.85 M(+4.3%) |
| July 2006 | - | -$17.90 K(-101.7%) | $1.78 M(-8.6%) |
| Apr 2006 | $1.95 M(-34.8%) | $1.05 M(+121.2%) | $1.95 M(+58.3%) |
| Jan 2006 | - | $476.90 K(+81.2%) | $1.23 M(+63.5%) |
| Oct 2005 | - | $263.20 K(+75.5%) | $751.60 K(+53.9%) |
| July 2005 | - | $150.00 K(-55.7%) | $488.40 K(-83.6%) |
| Apr 2005 | $2.98 M(+753.3%) | $338.40 K(>+9900.0%) | $2.98 M(+3.6%) |
| Jan 2005 | - | $0.00(0.0%) | $2.88 M(-3.0%) |
| Oct 2004 | - | $0.00(-100.0%) | $2.97 M(-0.4%) |
| July 2004 | - | $2.64 M(+1025.4%) | $2.98 M(+753.3%) |
| Apr 2004 | $349.60 K(+832.3%) | $235.00 K(+160.8%) | $349.60 K(+205.1%) |
| Jan 2004 | - | $90.10 K(+572.4%) | $114.60 K(+367.8%) |
| Oct 2003 | - | $13.40 K(+20.7%) | $24.50 K(+120.7%) |
| July 2003 | - | $11.10 K | $11.10 K |
| Apr 2003 | $37.50 K(+70.5%) | - | - |
| Apr 2002 | $22.00 K | - | - |
FAQ
- What is PharmaCyte Biotech annual cash flow from financing activities?
- What is the all time high annual CFF for PharmaCyte Biotech?
- What is PharmaCyte Biotech annual CFF year-on-year change?
- What is PharmaCyte Biotech quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for PharmaCyte Biotech?
- What is PharmaCyte Biotech quarterly CFF year-on-year change?
- What is PharmaCyte Biotech TTM cash flow from financing activities?
- What is the all time high TTM CFF for PharmaCyte Biotech?
- What is PharmaCyte Biotech TTM CFF year-on-year change?
What is PharmaCyte Biotech annual cash flow from financing activities?
The current annual CFF of PMCB is -$10.71 M
What is the all time high annual CFF for PharmaCyte Biotech?
PharmaCyte Biotech all-time high annual cash flow from financing activities is $87.31 M
What is PharmaCyte Biotech annual CFF year-on-year change?
Over the past year, PMCB annual cash flow from financing activities has changed by +$2.85 M (+21.03%)
What is PharmaCyte Biotech quarterly cash flow from financing activities?
The current quarterly CFF of PMCB is -$10.17 M
What is the all time high quarterly CFF for PharmaCyte Biotech?
PharmaCyte Biotech all-time high quarterly cash flow from financing activities is $87.36 M
What is PharmaCyte Biotech quarterly CFF year-on-year change?
Over the past year, PMCB quarterly cash flow from financing activities has changed by -$10.92 M (-1458.59%)
What is PharmaCyte Biotech TTM cash flow from financing activities?
The current TTM CFF of PMCB is -$27.16 M
What is the all time high TTM CFF for PharmaCyte Biotech?
PharmaCyte Biotech all-time high TTM cash flow from financing activities is $87.41 M
What is PharmaCyte Biotech TTM CFF year-on-year change?
Over the past year, PMCB TTM cash flow from financing activities has changed by -$26.10 M (-2469.93%)